M/S .pharma Associates,

M/S .pharma Associates is a specialty pharmaceutical company based in Colombo, Sri Lanka, focusing on the importation and distribution of finished pharmaceutical formulations across various therapeutic areas. Established in 1990, the company has developed a robust presence in the Sri Lankan pharmaceutical market, emphasizing the sales and market development of products in fields such as Cardiology, Oncology, Gastroenterology, Obstetrics & Gynaecology, Neurology, Paediatrics, Endocrinology, and Rheumatology. (pharmasl.lk)

The company operates as a pharmaceutical importer and distributor, sourcing finished pharmaceutical formulations from international suppliers, particularly from India. M/S .pharma Associates plays a significant role in Sri Lanka's pharmaceutical distribution network, ensuring the availability of a diverse range of medications to meet the healthcare needs of the population. Their portfolio includes specialized products such as biosimilars, oncology medications, ASD catheters, and cardiac stents, reflecting a commitment to providing advanced therapeutic options. (pharmasl.lk)

M/S .pharma Associates has established an extensive distribution network throughout Sri Lanka, encompassing major cities and regional centers. Their distribution network includes partnerships with local distributors in Colombo, Wellawatte Drugs and Peoples Medicals, as well as in suburbs like Nega Marketing Services and Harsha Distributors. Additionally, they have branches in Kurunegala, Akkaraipattu, Jaffna, Galle, and Kandy, ensuring comprehensive coverage across the island. (pharmasl.lk)

The company's logistics capabilities are designed to facilitate efficient delivery of pharmaceutical products to various healthcare providers, including hospitals, clinics, and pharmacies. By leveraging their own distribution network and collaborating with local partners, M/S .pharma Associates ensures timely and reliable access to essential medications, thereby supporting the healthcare infrastructure in Sri Lanka.

M/S .pharma Associates functions primarily as a pharmaceutical importer and distributor within Sri Lanka's pharmaceutical supply chain. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a steady supply of essential medications to meet the diverse healthcare needs of the Sri Lankan population. Their focus on specialized products, such as biosimilars and oncology medications, positions them as a key player in providing advanced therapeutic options in the market. (pharmasl.lk)

Through their extensive distribution network and strategic partnerships, M/S .pharma Associates plays a crucial role in bridging the gap between international pharmaceutical manufacturers and local healthcare providers, thereby contributing to the overall health and well-being of the community.

M/S .pharma Associates demonstrates a high level of sourcing concentration, with a significant portion of their pharmaceutical imports originating from a select group of Indian suppliers. The top three suppliers are:

• THE MADRAS PHARMACEUTICALS: $2.5 million (153 shipments, 58.0%)
• THE MADRAS PHARMACEUTICAL: $1.6 million (62 shipments, 36.8%)
• SOFTGEL HEALTHCARE PRIVATE LIMITED: $221,000 (11 shipments, 5.1%)

This concentration indicates a strategic choice by M/S .pharma Associates to establish strong, long-term relationships with these suppliers, ensuring consistent product quality and supply reliability. The substantial number of shipments from these suppliers suggests a stable and ongoing partnership, which is crucial for maintaining the continuity of pharmaceutical supplies in the Sri Lankan market.

However, such concentration also presents potential risks, including supply chain disruptions if any of these suppliers face operational challenges. To mitigate these risks, M/S .pharma Associates may consider diversifying their supplier base and exploring partnerships with additional manufacturers to enhance supply chain resilience.

M/S .pharma Associates' supply chain resilience is closely tied to the stability and reliability of their primary Indian suppliers. The company's sourcing strategy, which heavily relies on a few key suppliers, underscores the importance of these partnerships in ensuring a consistent supply of pharmaceutical products.

To bolster supply chain resilience, M/S .pharma Associates could consider diversifying their supplier base by engaging with additional manufacturers, both within India and internationally. This approach would mitigate potential risks associated with over-reliance on a limited number of suppliers and enhance the company's ability to adapt to market fluctuations and disruptions.

Additionally, exploring alternative shipping routes and logistics partners could provide greater flexibility and security in the supply chain, further strengthening the company's operational resilience.

The sourcing pattern of M/S .pharma Associates, characterized by a high concentration of imports from a select group of Indian suppliers, has several strategic implications. For M/S .pharma Associates, this strategy facilitates strong supplier relationships, ensuring consistent product quality and supply reliability. However, it also exposes the company to potential risks associated with supply chain disruptions if any of these suppliers encounter operational challenges.

For Indian exporters, the established partnerships with M/S .pharma Associates present opportunities to strengthen their market presence in Sri Lanka. By maintaining high standards of quality and reliability, Indian suppliers can enhance their competitiveness and appeal to M/S .pharma Associates as a preferred partner. Additionally, exploring opportunities to diversify their product offerings and align with the therapeutic areas prioritized by M/S .pharma Associates could further solidify these partnerships.

In Sri Lanka, the National Medicines Regulatory Authority (NMRA) serves as the primary regulatory body overseeing the pharmaceutical sector. Established under the NMRA Act No. 05 of 2015, the NMRA is responsible for ensuring the availability of efficacious, safe, and good-quality medicines to the public at affordable prices.

The NMRA's regulatory framework encompasses the evaluation, registration, and monitoring of medicinal products, medical devices, and related health products. This includes the assessment of product quality, efficacy, safety, and compliance with international standards. The Medicines Evaluation Committee (MEC), formed under the NMRA Act, conducts scientific and technical reviews, inspections, and surveillance activities to uphold these standards.

To import pharmaceutical products into Sri Lanka, companies must obtain the necessary import licenses from the NMRA. This process involves submitting detailed product information, including Certificates of Pharmaceutical Product (COPP), Certificates of Analysis (COA), Batch Release Certificates, and Product Registration Certificates, as applicable.

The NMRA recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized authorities to comply with Sri Lankan regulations. (freyrsolutions.com.lk)

Pharmaceutical products imported into Sri Lanka are subject to batch testing and stability requirements to ensure their quality and efficacy. The NMRA mandates that imported medicines undergo testing to verify their compliance with established standards. (nmra.gov.lk)

Labeling requirements include the use of the English language, with specific details such as product name, dosage form, strength, batch number, manufacturing and expiry dates, storage conditions, and the manufacturer's name and address. Additionally, serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market. (nmra.gov.lk)

Between 2024 and 2026, Sri Lanka implemented several regulatory changes affecting pharmaceutical imports. Notably, in October 2023, the Customs Department introduced a new rule requiring all documents necessary for clearing pharmaceutical imports, including registration certificates, shipment approvals, and import licenses, to be stamped with the NMRA CEO’s seal containing specific details. This change led to delays in clearing shipments at the Colombo Port, affecting supplies in the private sector.

These regulatory changes underscore the importance of staying informed about evolving import regulations and ensuring compliance to maintain uninterrupted supply chains.

M/S .pharma Associates' product strategy focuses on therapeutic areas with significant demand in the Sri Lankan market, including Cardiology, Oncology, Gastroenterology, Obstetrics & Gynaecology, Neurology, Paediatrics, Endocrinology, and Rheumatology. By importing specialized products such as biosimilars, oncology medications, ASD catheters, and cardiac stents, the company addresses critical healthcare needs and positions itself as a provider of advanced therapeutic options. (pharmasl.lk)

The company's emphasis on these therapeutic areas aligns with the growing healthcare demands in Sri Lanka, driven by an aging population and increasing prevalence of chronic diseases. By focusing on these segments, M/S .pharma Associates aims to enhance